Tarsus Pharmaceuticals (NASDAQ:TARS) CEO Bobak Azamian Sells 10,000 Shares of Company Stock

Tarsus Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • CEO Bobak Azamian sold 10,000 Tarsus shares for about $803,100 at an average price of $80.31 under a pre-arranged Rule 10b5-1 plan. He retained 817,991 shares after the sale.
  • Tarsus reported quarterly revenue of $194.57 million, above analyst expectations of $187.83 million, but EPS of -$14.40 missed the consensus estimate of -$1.46.
  • Analysts’ consensus rating was Moderate Buy, with an average price target of $104.57; shares traded at $78.20 in the article’s cited session.
  • Interested in Tarsus Pharmaceuticals? Here are five stocks we like better.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) CEO Bobak Azamian sold 10,000 shares of the business's stock in a transaction that occurred on Friday, November 13th. The shares were sold at an average price of $80.31, for a total value of $803,100.00. Following the sale, the chief executive officer owned 817,991 shares of the company's stock, valued at approximately $65,692,857.21. This represents a 1.21% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tarsus Pharmaceuticals Price Performance

Shares of TARS traded down $0.48 during trading hours on Tuesday, reaching $78.20. The stock had a trading volume of 542,217 shares, compared to its average volume of 871,204. Tarsus Pharmaceuticals, Inc. has a 12 month low of $53.89 and a 12 month high of $91.53. The firm has a 50-day simple moving average of $74.60 and a 200 day simple moving average of $68.05. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.96 and a quick ratio of 1.94.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported ($14.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.46) by ($12.94). Tarsus Pharmaceuticals had a negative net margin of 102.93% and a negative return on equity of 24.51%. The business had revenue of $194.57 million during the quarter, compared to analyst estimates of $187.83 million. On average, equities research analysts expect that Tarsus Pharmaceuticals, Inc. will post -15.64 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in TARS. BlackRock Inc. bought a new stake in Tarsus Pharmaceuticals during the second quarter worth $242,705,000. Jupiter Topco LLC bought a new position in Tarsus Pharmaceuticals in the 2nd quarter valued at $176,834,000. Janus Henderson Group PLC grew its stake in Tarsus Pharmaceuticals by 16.1% in the 1st quarter. Janus Henderson Group PLC now owns 2,240,963 shares of the company's stock valued at $157,223,000 after purchasing an additional 310,638 shares during the period. Bank of America Corp DE grew its stake in Tarsus Pharmaceuticals by 57.5% in the 1st quarter. Bank of America Corp DE now owns 1,194,377 shares of the company's stock valued at $83,786,000 after purchasing an additional 436,271 shares during the period. Finally, Goldman Sachs Group Inc. increased its position in shares of Tarsus Pharmaceuticals by 9.9% during the 3rd quarter. Goldman Sachs Group Inc. now owns 816,233 shares of the company's stock valued at $64,164,000 after purchasing an additional 73,540 shares during the last quarter. 90.01% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

TARS has been the subject of several recent research reports. The Goldman Sachs Group initiated coverage on shares of Tarsus Pharmaceuticals in a research report on Thursday, September 24th. They set a "buy" rating and a $116.00 target price for the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Tarsus Pharmaceuticals in a research note on Thursday, October 15th. Guggenheim lifted their price target on Tarsus Pharmaceuticals from $89.00 to $97.00 and gave the company a "buy" rating in a research note on Thursday, November 5th. Barclays assumed coverage on Tarsus Pharmaceuticals in a report on Wednesday, September 16th. They set an "overweight" rating and a $110.00 price objective for the company. Finally, Mizuho dropped their target price on Tarsus Pharmaceuticals from $100.00 to $98.00 and set an "outperform" rating on the stock in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $104.57.

Get Our Latest Analysis on TARS

Tarsus Pharmaceuticals Company Profile

(Get Free Report)

Tarsus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for diseases with significant unmet medical needs, particularly in eye care. The company's work includes therapies targeting Demodex mites, microscopic parasites associated with certain eye conditions. Its lead product, XDEMVY (lotilaner ophthalmic solution), is an FDA-approved prescription treatment for Demodex blepharitis, an eyelid condition. Tarsus has also evaluated lotilaner-based candidates for other conditions, including ocular rosacea and Lyme disease prevention.

Featured Articles

Insider Buying and Selling by Quarter for Tarsus Pharmaceuticals (NASDAQ:TARS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Tarsus Pharmaceuticals Right Now?

Before you consider Tarsus Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tarsus Pharmaceuticals wasn't on the list.

While Tarsus Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines